Alfred Chung, Assistant Professor

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Bristol Myers Squibb
    Topic:
    Research Funding
    Date added:
    02/27/2024
    Date updated:
    02/27/2024
  • Attribution:
    Self
    Type of financial relationship:
    Travel
    Ineligible company:
    Janssen
    Date added:
    02/27/2024
    Date updated:
    02/27/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Janssen
    Topic:
    Advisory Board
    Date added:
    02/27/2024
    Date updated:
    02/27/2024
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Janssen
    Topic:
    Research Funding
    Date added:
    02/27/2024
    Date updated:
    02/27/2024
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Abbvie
    Topic:
    Research Funding
    Date added:
    02/27/2024
    Date updated:
    02/27/2024
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Carsgen
    Topic:
    Research Funding
    Date added:
    02/27/2024
    Date updated:
    02/27/2024
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Caelum Biosciences
    Topic:
    Research Funding
    Date added:
    02/27/2024
    Date updated:
    02/27/2024
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Cellectis
    Topic:
    Research Funding
    Date added:
    02/27/2024
    Date updated:
    02/27/2024
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Merck
    Topic:
    Research Funding
    Date added:
    02/27/2024
    Date updated:
    02/27/2024
Return to Northern California Hematology Oncology Conference: A Tumor Board Case-Based Approach to the Latest Breakthroughs